Abstract
The NOD-like receptor protein 3 (NLRP3) inflammasome is a protein complex that regulates innate immune responses by activating caspase-1 and the inflammatory cytokines interleukin (IL)-1β and IL-18. Multiple studies have demonstrated the importance of the NLRP3 inflammasome in the development of immune and inflammation-related diseases, including arthritis, Alzheimer’s disease, inflammatory bowel disease, and other autoimmune and autoinflammatory diseases. This review first explains the activation and regulatory mechanism of the NLRP3 inflammasome. Secondly, we focus on the role of the NLRP3 inflammasome in various inflammation-related diseases. Finally, we look forward to new methods for targeting the NLRP3 inflammasome to treat inflammation-related diseases, and provide new ideas for clinical treatment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The First Affiliated Hospital of Xi’an Jiaotong University, Department of Hematology, Xi’an, China (GRID:grid.452438.c) (ISNI:0000 0004 1760 8119)
2 Northwest University, Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Faculty of Life Sciences and Medicine, Xi’an, China (GRID:grid.412262.1) (ISNI:0000 0004 1761 5538); Xi’an No. 3 Hospital, The Affiliated Hospital of Northwest University, Department of Neurology, Xi’an, China (GRID:grid.412262.1) (ISNI:0000 0004 1761 5538)
3 University of Granada, Biomedical Research Center, Health Sciences Technology Park, Granada, Spain (GRID:grid.4489.1) (ISNI:0000000121678994); Ibs. Granada and CIBERfes, Granada, Spain (GRID:grid.507088.2); UGC of Clinical Laboratories, University San Cecilio’s Hospital, Granada, Spain (GRID:grid.507088.2)
4 Affiliated Hospital, Yan’an University, Department of Cardiology, Yan’an, China (GRID:grid.440747.4) (ISNI:0000 0001 0473 0092)
5 Central Theater Command General Hospital of Chinese People’s Liberation Army, Department of Cardiothoracic Surgery, Wuhan, China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)





